Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01486329 | VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer | PHASE1 | COMPLETED | 72 | — | — | Dec 1, 2011 | Dec 1, 2014 | Jun 8, 2015 | 1 | Germany |
Number of dose-limiting toxicities and maximum tolerated dose
| Arm | Type | Description |
|---|---|---|
| VXM01 | EXPERIMENTAL | Investigational anti-angiogenic live cancer vaccine |
| Placebo | PLACEBO_COMPARATOR | Placebo control |
| Name | Type | Description |
|---|---|---|
| VXM01 | BIOLOGICAL | Live anti-angiogenic cancer vaccine drink solution, escalating dose |
| Placebo | BIOLOGICAL | Drink solution |
Inclusion Criteria: * Written informed consent, signed and dated * Locally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations * Male or post-menopausal female * Age above or equal to ...